I understand your frustration. There are many Abeta antibodies on the market, and the fact that progress in research on the subject has been trivial for the last decade says all. Weather this is down to the quality of the antibodies remains to be seen though. I think that the physical properties of Abeta is the major culprit preventing robust quantification through immuno assay. The discussion is also still on if the monomers or the oligomers are toxic (for those who have finally abandoned the idea that the amyloid plaque is the cause of AD). This means that antibodies to certain part of the Abeta peptide will be more useful than antibodies to the entire peptide. We have such different antibodies. I am happy to send you samples if you promise to provide evidence of their quality in your hands.

Thanks for your input and offer Jan. It's much appreciated, and I may well get back to you on this later. I think you're right about the physical properties of Abeta, as it undergoes dynamic changes during the progression from monomers to fibrils, ultimately, and you need to really know which species any antibody you use is recognising. I've used several antibodies at the TEM level which have labelled AD brain plaques beautifully and specifically, but now I need antibodies to recognise more upstream species of Abeta in cellular models of the disease. It's a bit of a long shot probably to find an antibody that will work well for the latter approaches and for correlative Western blotting, so will probably have to go down the 'panel of antibodies' approach, and determine which Abeta species each different antibody is recognising.

Cheers, Jules